We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$803K
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$673K |
| 2 |
Zai Lab
ZLAB
|
+$472K |
| 3 |
Stellus Capital Investment Corp
SCM
|
+$422K |
| 4 |
DRD
DRDGold
DRD
|
+$415K |
| 5 |
OXLC
Oxford Lane Capital
OXLC
|
+$359K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$1.16M |
| 2 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$664K |
| 3 |
BioNTech
BNTX
|
+$663K |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$645K |
| 5 |
Prothena Corp
PRTA
|
+$590K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Shattuck Labs
STTK
$717M
| $228K | 0.09% |
+7,854
| New | +$230K |
|
|
ISEE
252
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $228K | 0.09% |
36,079
-7,188
| -17% | -$46.4K |
|
|
ARNA
253
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $228K | 0.09% |
3,350
-923
| -22% | -$60.2K |
|
|
AFMD
254
DELISTED
Affimed
AFMD
| $227K | 0.09% |
2,676
-1,595
| -37% | -$146K |
|
255
Legend Biotech
LEGN
$3.72B
| $227K | 0.09% |
5,531
-4,485
| -45% | -$152K |
|
256
TG Therapeutics
TGTX
$8.55B
| $227K | 0.09% |
5,840
-1,028
| -15% | -$40.4K |
|
|
NGM
257
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $227K | 0.09% |
11,501
+627
| +6% | +$14.7K |
|
|
CCXI
258
DELISTED
ChemoCentryx, Inc.
CCXI
| $227K | 0.09% |
16,985
+12,216
| +256% | +$301K |
|
259
Relmada Therapeutics
RLMD
$549M
| $226K | 0.09% |
7,056
-1,891
| -21% | -$65.7K |
|
260
Xenon Pharmaceuticals
XENE
$6.3B
| $225K | 0.09% |
12,091
-12,728
| -51% | -$235K |
|
|
TPTX
261
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $225K | 0.09% |
2,880
+514
| +22% | +$38K |
|
262
Curis
CRIS
$9.06M
| $224K | 0.09% |
+69
| New | +$312K |
|
263
PMV Pharmaceuticals
PMVP
$63.5M
| $224K | 0.09% |
+6,556
| New | +$219K |
|
|
IMGN
264
DELISTED
Immunogen Inc
IMGN
| $224K | 0.09% |
33,943
-7,416
| -18% | -$51.7K |
|
265
Axsome Therapeutics
AXSM
$12.4B
| $223K | 0.09% |
3,313
-445
| -12% | -$26.7K |
|
266
Crinetics Pharmaceuticals
CRNX
$8.87B
| $223K | 0.09% |
11,810
-10,072
| -46% | -$177K |
|
267
Korro Bio
KRRO
$151M
| $223K | 0.09% |
448
+284
| +173% | +$139K |
|
|
GMDA
268
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $223K | 0.09% |
34,842
+1,800
| +5% | +$12.4K |
|
|
TVRD
269
Tvardi Therapeutics
TVRD
$23.9M
| $222K | 0.09% |
433
-127
| -23% | -$80.5K |
|
|
CLVS
270
DELISTED
Clovis Oncology, Inc.
CLVS
| $222K | 0.09% |
+38,303
| New | +$224K |
|
271
XBiotech
XBIT
$68.9M
| $221K | 0.09% |
13,346
-2,526
| -16% | -$42.8K |
|
|
RETA
272
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $221K | 0.09% |
1,560
-977
| -39% | -$110K |
|
273
Alector
ALEC
$169M
| $220K | 0.09% |
10,556
-9,361
| -47% | -$176K |
|
274
Immunocore
IMCR
$1.77B
| $220K | 0.09% |
+5,634
| New | +$217K |
|
275
Immunovant
IMVT
$8.27B
| $220K | 0.09% |
20,827
+14,684
| +239% | +$205K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.
Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.
- Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
- Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
- Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
- Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
- Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
- Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
- Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.